Treatment of recurrent respiratory papillomatosis with human leukocyte interferon. Results of a multicenter randomized clinical trial

G. B. Healy, R. D. Gelber, A. L. Trowbridge, K. M. Grundfast, Robert J. Ruben, K. N. Price

Research output: Contribution to journalArticle

121 Citations (Scopus)

Abstract

Recurrent respiratory papillomatosis is a relentless disease of viral origin in which squamous papillomas frequently obstruct the respiratory tract of children and young adults. No therapy has been proved to be curative for this process. Recent reports have suggested that interferon may cure or dramatically control airway papillomatosis. We evaluated the efficac of human leukocyte interferon in the treatment of respiratory papillomatosis. One hundred twenty-three patients were randomly assigned to receive treatment with either surgery plus interferon or surgery alone. Interferon (2 x 106 IU per square meter of body-surface area) was given daily for one week, then three times per week for one year; treatment was followed by a year of observation, without the drug. Both study groups underwent serial endoscopy to remove papillomas and to document the efficacy of treatment during the two years of study. During the first six months, the growth rate of papillomas in the interferon group was significantly lower than in the control group (P = 0.0007). This difference diminished during the second six months and was no longer statistically significant (P = 0.68). Our data do not show that interferon is either curative or of substantial value as an adjunctive agent in the long-term management of recurrent respiratory papillomatosis. The initial benefit of interferon is not sustained.

Original languageEnglish (US)
Pages (from-to)401-407
Number of pages7
JournalNew England Journal of Medicine
Volume319
Issue number7
StatePublished - 1988

Fingerprint

Interferon-alpha
Interferons
Randomized Controlled Trials
Papilloma
Therapeutics
Airway Management
Body Surface Area
Virus Diseases
Respiratory System
Endoscopy
Recurrent respiratory papillomatosis
Young Adult
Observation
Control Groups
Growth
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Treatment of recurrent respiratory papillomatosis with human leukocyte interferon. Results of a multicenter randomized clinical trial. / Healy, G. B.; Gelber, R. D.; Trowbridge, A. L.; Grundfast, K. M.; Ruben, Robert J.; Price, K. N.

In: New England Journal of Medicine, Vol. 319, No. 7, 1988, p. 401-407.

Research output: Contribution to journalArticle

Healy, G. B. ; Gelber, R. D. ; Trowbridge, A. L. ; Grundfast, K. M. ; Ruben, Robert J. ; Price, K. N. / Treatment of recurrent respiratory papillomatosis with human leukocyte interferon. Results of a multicenter randomized clinical trial. In: New England Journal of Medicine. 1988 ; Vol. 319, No. 7. pp. 401-407.
@article{6dd4dcaa191d40069d8f046dfc298909,
title = "Treatment of recurrent respiratory papillomatosis with human leukocyte interferon. Results of a multicenter randomized clinical trial",
abstract = "Recurrent respiratory papillomatosis is a relentless disease of viral origin in which squamous papillomas frequently obstruct the respiratory tract of children and young adults. No therapy has been proved to be curative for this process. Recent reports have suggested that interferon may cure or dramatically control airway papillomatosis. We evaluated the efficac of human leukocyte interferon in the treatment of respiratory papillomatosis. One hundred twenty-three patients were randomly assigned to receive treatment with either surgery plus interferon or surgery alone. Interferon (2 x 106 IU per square meter of body-surface area) was given daily for one week, then three times per week for one year; treatment was followed by a year of observation, without the drug. Both study groups underwent serial endoscopy to remove papillomas and to document the efficacy of treatment during the two years of study. During the first six months, the growth rate of papillomas in the interferon group was significantly lower than in the control group (P = 0.0007). This difference diminished during the second six months and was no longer statistically significant (P = 0.68). Our data do not show that interferon is either curative or of substantial value as an adjunctive agent in the long-term management of recurrent respiratory papillomatosis. The initial benefit of interferon is not sustained.",
author = "Healy, {G. B.} and Gelber, {R. D.} and Trowbridge, {A. L.} and Grundfast, {K. M.} and Ruben, {Robert J.} and Price, {K. N.}",
year = "1988",
language = "English (US)",
volume = "319",
pages = "401--407",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "7",

}

TY - JOUR

T1 - Treatment of recurrent respiratory papillomatosis with human leukocyte interferon. Results of a multicenter randomized clinical trial

AU - Healy, G. B.

AU - Gelber, R. D.

AU - Trowbridge, A. L.

AU - Grundfast, K. M.

AU - Ruben, Robert J.

AU - Price, K. N.

PY - 1988

Y1 - 1988

N2 - Recurrent respiratory papillomatosis is a relentless disease of viral origin in which squamous papillomas frequently obstruct the respiratory tract of children and young adults. No therapy has been proved to be curative for this process. Recent reports have suggested that interferon may cure or dramatically control airway papillomatosis. We evaluated the efficac of human leukocyte interferon in the treatment of respiratory papillomatosis. One hundred twenty-three patients were randomly assigned to receive treatment with either surgery plus interferon or surgery alone. Interferon (2 x 106 IU per square meter of body-surface area) was given daily for one week, then three times per week for one year; treatment was followed by a year of observation, without the drug. Both study groups underwent serial endoscopy to remove papillomas and to document the efficacy of treatment during the two years of study. During the first six months, the growth rate of papillomas in the interferon group was significantly lower than in the control group (P = 0.0007). This difference diminished during the second six months and was no longer statistically significant (P = 0.68). Our data do not show that interferon is either curative or of substantial value as an adjunctive agent in the long-term management of recurrent respiratory papillomatosis. The initial benefit of interferon is not sustained.

AB - Recurrent respiratory papillomatosis is a relentless disease of viral origin in which squamous papillomas frequently obstruct the respiratory tract of children and young adults. No therapy has been proved to be curative for this process. Recent reports have suggested that interferon may cure or dramatically control airway papillomatosis. We evaluated the efficac of human leukocyte interferon in the treatment of respiratory papillomatosis. One hundred twenty-three patients were randomly assigned to receive treatment with either surgery plus interferon or surgery alone. Interferon (2 x 106 IU per square meter of body-surface area) was given daily for one week, then three times per week for one year; treatment was followed by a year of observation, without the drug. Both study groups underwent serial endoscopy to remove papillomas and to document the efficacy of treatment during the two years of study. During the first six months, the growth rate of papillomas in the interferon group was significantly lower than in the control group (P = 0.0007). This difference diminished during the second six months and was no longer statistically significant (P = 0.68). Our data do not show that interferon is either curative or of substantial value as an adjunctive agent in the long-term management of recurrent respiratory papillomatosis. The initial benefit of interferon is not sustained.

UR - http://www.scopus.com/inward/record.url?scp=0023679775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023679775&partnerID=8YFLogxK

M3 - Article

VL - 319

SP - 401

EP - 407

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 7

ER -